There are 2789 resources available
616P - Real-world utilization of advanced therapies by metastatic site and age among patients with metastatic castration-sensitive prostate cancer (mCSPC): A Medicare database analysis
Presenter: Daniel George
Session: ePoster Display
617P - Genomic profiling of circulating tumor DNA in advanced genitourinary cancer patients: SCRUM-Japan MONSTAR SCREEN Nationwide Cancer Genome Screening Project
Presenter: Taigo Kato
Session: ePoster Display
618P - Apalutamide (APA) for advanced prostate cancer in older patients (pts): Combined analysis of TITAN & SPARTAN
Presenter: John Shen
Session: ePoster Display
619P - Immune profiling of advanced prostate cancer harbouring homologous recombination deficiency
Presenter: Maryam Soleimani
Session: ePoster Display
620P - MGC018, an anti-B7-H3 antibody-drug conjugate (ADC), in patients with advanced solid tumors: Preliminary results of phase I cohort expansion
Presenter: Eugene Shenderov
Session: ePoster Display
621P - Efficacy and safety of relugolix vs leuprolide (LEU) in men with advanced prostate cancer (APC): Clinical subgroup analysis from the phase III HERO study
Presenter: Bertrand Tombal
Session: ePoster Display
622P - Geographical assessment of efficacy and safety of relugolix: A subgroup analysis from the randomized, phase III HERO study vs leuprolide (LEU) in men with advanced prostate cancer (APC)
Presenter: Bertrand Tombal
Session: ePoster Display
623P - Real-world treatment patterns in metastatic hormone-sensitive prostate cancer (mHSPC) patients in the US, Germany, France, China and Japan
Presenter: Peter Goebell
Session: ePoster Display
624P - Prevalence and clinical impact of PTEN status in patients (pts) with de novo metastatic hormone sensitive prostate cancer (mHSPC)
Presenter: Jonathan Thouvenin
Session: ePoster Display
625P - TMPRSS2-ERG expression and clinical evolution of metastatic hormone sensitive prostate cancer
Presenter: Caterina Aversa
Session: ePoster Display